Patents by Inventor Jacques Dumas

Jacques Dumas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD38 ANTIBODIES AND FORMULATIONS
    Publication number: 20230416395
    Abstract: Provided herein are antibodies that specifically bind human CD38, formulations and unit dosage forms comprising the antibodies, methods of preparing the antibodies and methods of using the antibodies.
    Type: Application
    Filed: April 14, 2023
    Publication date: December 28, 2023
    Inventors: Marielle CHIRON BLONDEL, Cendrine LEMOINE, Angela VIRONE-ODDOS, Béatrice CAMERON, Jacques DUMAS, Alain FOURNIER, Jonathan KINGSBURY, Brian MURRAY, Nathan OSTBERG, Sanket PATKE, Zichuan ZHANG
  • Anti-CD38 antibodies and formulations
    Patent number: 11655302
    Abstract: Provided herein are antibodies that specifically bind human CD38, formulations and unit dosage forms comprising the antibodies, methods of preparing the antibodies and methods of using the antibodies.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: May 23, 2023
    Assignee: SANOFI
    Inventors: Marielle Chiron Blondel, Cendrine Lemoine, Angela Virone-Oddos, Béatrice Cameron, Jacques Dumas, Alain Fournier, Jonathan Kingsbury, Brian Murray, Nathan Ostberg, Sanket Patke, Zichuan Zhang
  • ANTI-CD38 ANTIBODIES AND FORMULATIONS
    Publication number: 20200399391
    Abstract: Provided herein are antibodies that specifically bind human CD38, formulations and unit dosage forms comprising the antibodies, methods of preparing the antibodies and methods of using the antibodies.
    Type: Application
    Filed: June 9, 2020
    Publication date: December 24, 2020
    Inventors: Marielle CHIRON BLONDEL, Cendrine LEMOINE, Angela VIRONE-ODDOS, Béatrice CAMERON, Jacques DUMAS, Alain FOURNIER, Jonathan KINGSBURY, Brian MURRAY, Nathan OSTBERG, Sanket PATKE, Zichuan ZHANG
  • Aryl ureas with angiogenisis inhibiting activity
    Patent number: 10653684
    Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: May 19, 2020
    Assignee: Bayer Healthcare LLC
    Inventors: Jacques Dumas, William J. Scott, James Elting, Holia Hatoum-Makdad
  • ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY
    Publication number: 20180296541
    Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
    Type: Application
    Filed: July 18, 2014
    Publication date: October 18, 2018
    Applicant: Bayer Healthcare LLC
    Inventors: Jacques Dumas, William Scott, James Elting, Holia Hatoum-Makdad
  • PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS
    Publication number: 20170165243
    Abstract: This invention relates to novel pharmaceutical compositions comprising a solid dispersion of the compound of Formula I below, to processes for preparing these novel pharmaceutical compositions and to their use for treating hyper-proliferative disorders, such as cancer, either as a sole agent or in combination with other therapies.
    Type: Application
    Filed: January 27, 2017
    Publication date: June 15, 2017
    Applicant: Bayer HealthCare, LLC
    Inventors: Jacques DUMAS, Paul EHRLICH, Suaanne ZULEGER
  • ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY
    Publication number: 20160015697
    Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
    Type: Application
    Filed: July 18, 2014
    Publication date: January 21, 2016
    Applicant: Bayer Healthcare LLC
    Inventors: Jacques Dumas, William Scott, James Elting, Holia Hatoum-Makdad
  • Aryl ureas as kinase inhibitors
    Patent number: 9181188
    Abstract: This invention relates to new aryl ureas and methods for their synthesis. The inventive compounds are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: November 10, 2015
    Assignee: Bayer Healthcare LLC
    Inventors: Jacques Dumas, William J. Scott, Du-Schieng Chien, Ala Nassar, Wendy Lee, Susan Bjorge, Laszlo L. Musza, Bernd Riedl
  • OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
    Publication number: 20140329866
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: July 17, 2014
    Publication date: November 6, 2014
    Applicant: BAYER HEALTHCARE LLC
    Inventors: Bernd RIEDL, Jacques DUMAS, Uday KHIRE, Timothy LOWINGER, William J. SCOTT, Roger A. SMITH, Jill E. WOOD
  • Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
    Patent number: 8841330
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: September 23, 2014
    Assignee: Bayer Healthcare LLC
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood
  • Diaryl ureas for diseases mediated by PDGFR
    Patent number: 8796250
    Abstract: The present invention provides methods for treating and/or preventing conditions and diseases in humans and other mammals that are associated with and/or mediated by signal transduction pathways comprising platelet-derived growth factor receptor (PDGFR) by administering diaryl ureas of Formula I. The present invention also provides devices and methods for treating, ameliorating, preventing, or modulating restenosis following angioplastic surgery or other invasive procedures that affect or injure the vascular system, and graft rejection following transplantation of a donor tissue into a host, where a stent or other omplantable device comprises an effective amount of diaryl ureas of Formula I.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: August 5, 2014
    Assignee: Bayer Healthcare LLC
    Inventors: Scott Wilhelm, Jacques Dumas, Gaetan Ladouceur, Mark Lynch, William Scott
  • Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
    Patent number: 8637553
    Abstract: A compound of Formula (I): salts thereof, prodrugs thereof, metabolites thereof, pharmaceutical compositions containing such a compound, and use of such compound and compositions to treat diseases mediated by raf, VEGFR, PDGFR, p38 and flt-3.
    Type: Grant
    Filed: July 22, 2004
    Date of Patent: January 28, 2014
    Assignee: Bayer Healthcare LLC
    Inventors: Stephen Boyer, Jacques Dumas, Bernd Riedl, Scott Wilhelm
  • Aryl ureas with angiogenesis inhibiting activity
    Patent number: 8618141
    Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: December 31, 2013
    Assignee: Bayer Healthcare LLC
    Inventors: Jacques Dumas, William J. Scott, James Elting, Holia Hatoum-Makdad
  • Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
    Patent number: 8580798
    Abstract: Substituted pyrimidine derivatives of formula (I), salts, metabolites, prodrugs and diastereoisomeric forms (both isolated stereoisomers and mixtures of stereoisomers) thereof (wherein A=pyrimidine) pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with other active ingredients, e.g., cytotoxic therapies.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: November 12, 2013
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Roger Smith, Jacques Dumas, Gan Wang, Wendy Lee, Karl Miranda
  • Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
    Patent number: 8431695
    Abstract: This invention relates to novel compounds of formula (I). Formula (I) in which the variable groups are as defined in the specification and claims, to pharmaceutical compositions containing them, and to a method of treatment using them for treatment of cancer.
    Type: Grant
    Filed: November 2, 2006
    Date of Patent: April 30, 2013
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Stephen O'Connor, Jacques Dumas, Wendy Lee, Julie Dixon, David Cantin, David Gunn, Jennifer Burke, Barton Phillips, Derek Lowe, Tatiana Shelekhin, Gan Wang, Xin Ma, Shihong Ying, Andrea McClure, Furahi Achebe, Mario Lobell, Frederick Ehrgott, Christiana Iwuagwu, Kyle Parcella
  • RHO-KINASE INHIBITORS
    Publication number: 20120302587
    Abstract: Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.
    Type: Application
    Filed: August 6, 2012
    Publication date: November 29, 2012
    Inventors: Dhanapalan NAGARAHNAM, Jacques Dumas, Holia Hatoum-Mokdad, Stephen Boyer, Hans Pluempe
  • ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY
    Publication number: 20120289552
    Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
    Type: Application
    Filed: July 18, 2012
    Publication date: November 15, 2012
    Applicant: BAYER HEALTHCARE LLC
    Inventors: Jacques DUMAS, William J. SCOTT, James ELTING, Holia HATOUM-MAKDAD
  • INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
    Publication number: 20120270878
    Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: July 2, 2012
    Publication date: October 25, 2012
    Applicant: BAYER HEALTHERCARE LLC
    Inventors: Scott MILLER, Martin OSTERHOUT, Jacques DUMAS, Uday KHIRE, Timothy B. LOWINGER, William J. SCOTT, Roger A. SMITH, Jill E. WOOD, David E. GUNN, Holia HATOUM-MOKDAD, Marell RODRIGUEZ, Robert SIBLEY, Ming WANG, Tiffany TURNER, Catherine BRENNAN
  • Aryl ureas with angiogenisis inhibiting activity
    Patent number: 8242147
    Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: August 14, 2012
    Assignee: Bayer Healthcare LLC
    Inventors: Jacques Dumas, William J. Scott, James Elting, Holia Hatoum-Makdad
  • Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders
    Patent number: 8207172
    Abstract: The invention relates to novel heterocycles of formula (I) processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders.
    Type: Grant
    Filed: August 19, 2005
    Date of Patent: June 26, 2012
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Chengzhi Zhang, Jacques Dumas, Qingming Zhu, Roger Smith, Qingjie Liu, Sharad Verma, Jason Duquette, Qian Zhao, Dongping Fan, Georgiy Bondar, Philip Coish